R-Tech Ueno: Start of the Patient Enrollment of a Phase I/II Clinical Study of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) in U.S. for the Treatment of Severe Dry Eye
5/20/2013 10:46:40 AM
More...
|
R-Tech Ueno Receives FDA IND Approval for RU-101 (r-HSA) to Treat Severe Dry Eye
4/26/2013 10:10:16 AM
More...
|
R-Tech Ueno: Start of the Patient Enrollment of a Phase 3 Clinical Study of Unoprostone (Development Code UF-021) Ophthalmic Solution for the Treatment of Retinitis Pigmentosa
3/18/2013 10:27:16 AM
More...
|
R-Tech Ueno: Announcement of Commercial Availability of RESCULA® Eye Drops in the U.S. Market
2/21/2013 9:09:39 AM
More...
|
R-Tech Ueno: Lawsuit Claiming Infringement of AMITIZA® Capsules Patents
2/12/2013 10:06:08 AM
More...
|
R-Tech Ueno: Adoption of the Unoprostone Ophthalmic Solution in the 3rd A-STEP Public Recruitment in FY2012
2/1/2013 9:13:56 AM
More...
|
R-Tech Ueno: Announcement of Approval of sNDA for RESCULA® Ophthalmic Solution and Start of Commercialization
12/19/2012 9:51:34 AM
More...
|
R-Tech Ueno: Notification of Collaborative Study With Tohoku University on a New Drug Delivery System for Unoprostone
7/12/2012 10:26:30 AM
More...
|
R-Tech Ueno Announces Result of Arbitration Against Takeda Pharmaceutical Co. Ltd. (TKDG.DE)
7/6/2012 9:34:25 AM
More...
|
R-Tech Ueno: Announcement of Additional Extension of the Date of the Deadline for Rendering the Arbitration Decision Against Takeda Pharmaceutical Co. Ltd. (TKDG.DE)
7/2/2012 11:06:09 AM
More...
|
|